Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
clinical trials
fda
4
×
life sciences
national blog main
boston blog main
biotech
boston top stories
detroit blog main
detroit top stories
drugs
indiana blog main
indiana top stories
raleigh-durham blog main
raleigh-durham top stories
acute hepatic porphyrias
akin akinc
alnylam pharmaceuticals
alprazolam
amgen
aminolevulinic acid
bempedoic acid
blueprint medicines
boston
boulder/denver blog main
boulder/denver top stories
cancer
cgrp inhibitors
cholesterol
chronic migraine
colucid pharmaceuticals
companion diagnostic
corticosteroids
detroit
dna sequencing
drug enforcement administration
eli lilly
entrectinib
esperion therapeutics
express scripts
ezetimibe
What
drug
fda
second
4
×
approval
approved
medicine
new
nod
oks
acute
addresses
ago
alnylam
cancer
causes
cholesterol
combo
condition
decades
deeper
dna
eli
esperion
esperion’s
fingerprint
friday
genetic
giant
giving
going
indicated
interference
lasmiditan
levels
lilly
lilly’s
lowering
matter
medication
medicines
Language
unset
Current search:
second
×
fda
×
@xconomy.com
4 years ago
Esperion’s Combo Pill for Lowering Cholesterol Levels Wins FDA Nod
@xconomy.com
4 years ago
FDA OKs Lilly’s Lasmiditan, First New Acute Migraine Drug in Decades
@xconomy.com
5 years ago
Genetic Medicine: FDA OKs 2nd Cancer Drug that Targets DNA, not Tissues
@xconomy.com
5 years ago
Alnylam Won’t Seek Quick FDA Nod For Second RNAi Drug